TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15063253

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11552193

Group type: EXPERIMENTAL
Intervention: Mental practice for line‐tracing training
Number of subjects: 3
Study: 9610348

Group type: EXPERIMENTAL
Intervention: Experimental venous hypertension
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Patients with LDS
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Patients with VVs
Number of subjects: 55

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 55
Study: 8111946

Group type: EXPERIMENTAL
Intervention: EMLA patch
Number of subjects: 178

Group type: COMPARATOR
Intervention: EMLA cream (5% with Tegaderm)
Number of subjects: 178
Study: 3292981

Group type: EXPERIMENTAL
Intervention: Dilapan
Number of subjects: 54

Group type: COMPARATOR
Intervention: Laminaria
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dilapan (nulliparous women)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Laminaria (nulliparous women)
Number of subjects: 54
Study: 1098397

Group type: EXPERIMENTAL
Intervention: Practolol (beta-1-blocker)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Practolol + Salbutamol (beta-2-stimulating drug)
Number of subjects: 19
Study: 31711707

Group type: EXPERIMENTAL
Intervention: KP-10 (5 μg/kg body weight), injected once weekly for one month
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 12
Study: 30927509

Group type: EXPERIMENTAL
Intervention: Telephone consultations with physiotherapists involving education, advice, and prescription of a strengthening and physical activity program over 26 weeks.
Number of subjects: 84
Study: 27486011

Group type: EXPERIMENTAL
Intervention: Functional strength training program
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Resistance strength training program
Number of subjects: 129

Group type: COMPARATOR
Intervention: Stretching control group
Number of subjects: 129
Study: 26416154

Group type: EXPERIMENTAL
Intervention: Brimonidine gel 0.33%
Number of subjects: 92

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 92
Study: 24249434

Group type: COMPARATOR
Intervention: Mitiglinide alone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sitagliptin alone
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination of mitiglinide and sitagliptin
Number of subjects: 26
Study: 21135051

Group type: EXPERIMENTAL
Intervention: Low muscle glycogen levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged, exhausting exercise
Number of subjects: 0
Study: 19634963

Group type: EXPERIMENTAL
Intervention: Project Support intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Existing services comparison condition
Number of subjects: 66
Study: 16460701

Group type: EXPERIMENTAL
Intervention: Traditional morphometric methods
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3D surface models of the CC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Statistical maps of the CC
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (26 boys, aged 11.0 ± 2.5 years)
Number of subjects: 24
Study: 15257792

Group type: EXPERIMENTAL
Intervention: Quinine treatment at 10 mg/kg thrice daily for 7 days
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Quinine treatment at 10 mg/kg twice daily for 7 days
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Quinine treatment at 15 mg/kg once daily for 7 days
Number of subjects: 93
Study: 11398082

Group type: EXPERIMENTAL
Intervention: APC 366 (5 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9246224

Group type: EXPERIMENTAL
Intervention: midazolam
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: propofol
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: thiopental
Number of subjects: 47
Study: 8083025

Group type: EXPERIMENTAL
Intervention: Positive symptoms (hallucinations and delusions)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Negative symptoms (blunted affect and emotional withdrawal)
Number of subjects: 20
Study: 3438712

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 72
Study: 29557230

Group type: EXPERIMENTAL
Intervention: 200 mg vaginal progesterone effervescent tablet daily (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 250 mg IM 17‐OHPC weekly (Group B)
Number of subjects: 100
Study: 27040576

Group type: EXPERIMENTAL
Intervention: Hyperuricemia (UA >7 mg/dl in men and >6 mg/dl in women)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Normouricemic patients (UA ≤7 mg/dl in men and ≤6 mg/dl in women)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Patients with CKD
Number of subjects: 281

Group type: COMPARATOR
Intervention: Patients without CKD
Number of subjects: 281
Study: 24624993

Group type: EXPERIMENTAL
Intervention: Group-based memory training programme
Number of subjects: 40
Study: 22094494

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (UCM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Immediate cord clamping
Number of subjects: 24
Study: 20844462

Group type: EXPERIMENTAL
Intervention: rMenB+OMV
Number of subjects: 60

Group type: COMPARATOR
Intervention: rMenB
Number of subjects: 60
Study: 18508198

Group type: EXPERIMENTAL
Intervention: Therapeutic dose of ultrasound to the right supraspinatus trigger point
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham (null) exposure
Number of subjects: 50
Study: 15623811

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol therapy (0.05, 0.10, 0.15, and 0.20 mg/d for 4 consecutive days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 36
Study: 14504183

Group type: EXPERIMENTAL
Intervention: Low-dose AdVEGF121 (4x10^9 PU)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: High-dose AdVEGF121 (4x10^10 PU)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All groups (Low-dose, High-dose, Placebo)
Number of subjects: 105
Study: 12616334

Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Number of subjects: 24

Group type: COMPARATOR
Intervention: Amphetamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 24
Study: 9863926

Group type: EXPERIMENTAL
Intervention: TPS (Tissue Polypeptide Specific Antigen)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: CA 15-3
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: MCA (Mucin-like Associated Antigen)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Simultaneous determination of TPS and CA 15-3
Number of subjects: 139
Study: 7890083

Group type: EXPERIMENTAL
Intervention: Modified human tubal fluid medium devoid of glucose and phosphate ions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control medium (not specified)
Number of subjects: 10
Study: 2499174

Group type: EXPERIMENTAL
Intervention: Plain yogurt (Y)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sweet acidophilus milk (SAM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lactase tablet (LT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydrolyzed-lactose milk (HLM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole milk (WM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of yogurt and hydrolyzed-lactose milk
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Microbial endogenous lactase in yogurt
Number of subjects: 10
Study: 336322

Group type: EXPERIMENTAL
Intervention: MK-231 (Sulindac), 200-400 mg daily
Number of subjects: 25
Study: 31324986

Group type: EXPERIMENTAL
Intervention: Xenogenic graft plus modified perforated membranes (MPM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Xenogenic graft plus standard collagen membranes (CM)
Number of subjects: 15
Study: 29307157

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation therapy program (exercise intervention) for 8 weeks, including compensatory training, enhancement of visual and somatosensory function, and balance training.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention during the study period).
Number of subjects: 24
Study: 25607608

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg sc every 6 months
Number of subjects: 228

Group type: COMPARATOR
Intervention: Denosumab (crossover group)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 228
Study: 23340810

Group type: EXPERIMENTAL
Intervention: Intervention group received 300g of vegetables and 25ml of plant oil rich in polyunsaturated fatty acids per day for 8 weeks.
Number of subjects: 97

Group type: COMPARATOR
Intervention: Information only group (control).
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Diabetic individuals with MN frequency above the high 50th percentile.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Non-diabetic individuals with MN frequency above the 50th percentile.
Number of subjects: 97
Study: 21756567

Group type: EXPERIMENTAL
Intervention: Active cranial electrotherapy stimulation (CES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham cranial electrotherapy stimulation (CES)
Number of subjects: 0
Study: 19363565

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Home aerobic exercise
Number of subjects: 30
Study: 16461847

Group type: EXPERIMENTAL
Intervention: HT-treated (ramipril, 5 to 10 mg/d during 3 months; n=12)
Number of subjects: 34

Group type: COMPARATOR
Intervention: HT-placebo (n=10)
Number of subjects: 34
Study: 15268921

Group type: EXPERIMENTAL
Intervention: levodopa infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: control (pre-levodopa)
Number of subjects: 18
Study: 11684280

Group type: EXPERIMENTAL
Intervention: Real-time quantitative PCR assays for FLT3 ITDs
Number of subjects: 4
Study: 9282438

Group type: EXPERIMENTAL
Intervention: Hands immersed in water at 10 degrees C
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Hands immersed in water at 20 degrees C
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Hands immersed in water at 30 degrees C
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control condition (without hand immersion)
Number of subjects: 4
Study: 8287214

Group type: EXPERIMENTAL
Intervention: Domiciliary thrombolysis with 30 units anistreplase intravenously
Number of subjects: 311

Group type: COMPARATOR
Intervention: Hospital thrombolysis with 30 units anistreplase intravenously
Number of subjects: 311
Study: 31744812

Group type: EXPERIMENTAL
Intervention: Breads made with roller‐milled wholegrain flour
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Stone‐ground wholegrain bread
Number of subjects: 15
Study: 30396663

Group type: EXPERIMENTAL
Intervention: CCTA with FFRCT
Number of subjects: 50

Group type: COMPARATOR
Intervention: CCTA alone
Number of subjects: 50
Study: 26342630

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 13
Study: 24967366

Group type: EXPERIMENTAL
Intervention: Group II - parents provided with detailed information about anesthesia administration, drugs used, side effects, and complications.
Number of subjects: 146

Group type: COMPARATOR
Intervention: Group I - parents received standard consultation form with medical history and physical exam findings.
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Group II - parents with education levels up to high school.
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Group II - parents with higher education levels.
Number of subjects: 146
Study: 22837190

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (60 min at moderate intensity, five times/week for 12 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 75
Study: 20458201

Group type: EXPERIMENTAL
Intervention: Integrated motivational interviewing and cognitive behavior therapy
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Therapist-rated alliance
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Symptom severity and substance use measures
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Client ratings of alliance
Number of subjects: 116
Study: 18227326

Group type: EXPERIMENTAL
Intervention: Parasagittal interlaminar (PIL) approach
Number of subjects: 60
Study: 16186374

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) 4, 16, or 32 mg/d
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 12860211

Group type: COMPARATOR
Intervention: Tirofiban
Number of subjects: 3739

Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 3739
Study: 10947521

Group type: EXPERIMENTAL
Intervention: Condom skills training
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Communication pathway
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Both pathways
Number of subjects: 510
Study: 8902152

Group type: EXPERIMENTAL
Intervention: Saturated fatty acid diet (SAT)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid diet (PUFA)
Number of subjects: 19
Study: 1665400

Group type: EXPERIMENTAL
Intervention: Hep‐B Vax vaccine administered at 0, 1, and 6 months after birth (5 or 2.5 micrograms in pilot study, 5 micrograms in main study)
Number of subjects: 38000

Group type: EXPERIMENTAL
Intervention: Hep‐B Vax vaccine
Number of subjects: 38000

Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 38000
Study: 6241271

Group type: EXPERIMENTAL
Intervention: Transfused hemodialyzed patients
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both transfused and nontransfused hemodialyzed subjects
Number of subjects: 29
Study: 31656954

Group type: EXPERIMENTAL
Intervention: Group antenatal care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Convenience sample of women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Providers
Number of subjects: 0
Study: 29410192

Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 36

Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 36
Study: 27025835

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) 60 mg + Sofosbuvir (SOF) 400 mg for 12 weeks
Number of subjects: 151
Study: 24925124

Group type: EXPERIMENTAL
Intervention: Low glycaemic load (LGL) breakfast
Number of subjects: 65

Group type: COMPARATOR
Intervention: High glycaemic load (HGL) breakfast
Number of subjects: 65

Group type: COMPARATOR
Intervention: No energy control
Number of subjects: 65
Study: 22931582

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted influenza A H1N1/2009 vaccine
Number of subjects: 30
Study: 20538134

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg) plus Simvastatin (40 mg)
Number of subjects: 1570
Study: 17933700

Group type: EXPERIMENTAL
Intervention: Indinavir 600 mg BID + Ritonavir 100 mg BID
Number of subjects: 14

Group type: COMPARATOR
Intervention: Indinavir 400 mg BID + Ritonavir 100 mg BID
Number of subjects: 14
Study: 15686782

Group type: EXPERIMENTAL
Intervention: Medical treatment with anti‐anginal drugs (not specified which drugs or dosages)
Number of subjects: 7669

Group type: EXPERIMENTAL
Intervention: Invasive treatments (not specified)
Number of subjects: 7669
Study: 12069465

Group type: EXPERIMENTAL
Intervention: CO(2) group
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 165
Study: 9867093

Group type: EXPERIMENTAL
Intervention: Fructose-sorbitol (F-S) mixture (25 g fructose and 5 g sorbitol)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fructose-sorbitol (F-S) malabsorption
Number of subjects: 15

Group type: COMPARATOR
Intervention: Jejunal hypersensitivity
Number of subjects: 15

Group type: COMPARATOR
Intervention: Jejunal dysmotility
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cumulative symptom scores and breath hydrogen production
Number of subjects: 15
Study: 7608320

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (without EMLA)
Number of subjects: 12
Study: 2633458

Group type: EXPERIMENTAL
Intervention: 4 mg molsidomine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 120 mg isosorbide dinitrate retard
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 334229

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 37
Study: 30578462

Group type: EXPERIMENTAL
Intervention: Betrixaban (35–42 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin (6–14 days)
Number of subjects: 0
Study: 29903591

Group type: EXPERIMENTAL
Intervention: Combined training (aerobic and resistance exercises)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study: 26832435

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 2090

Group type: COMPARATOR
Intervention: Standard surgical dressings
Number of subjects: 2090
Study: 24276307

Group type: EXPERIMENTAL
Intervention: High Training Load (HTL)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Moderate Training Load (MTL)
Number of subjects: 14
Study: 22674141

Group type: EXPERIMENTAL
Intervention: Eltrombopag 12.5 mg once daily for 2 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 mg once daily for 2 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Eltrombopag 37.5 mg once daily for 2 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 38
Study: 20953062

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80mg/day) for 3 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 17403003

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (20 mg) every 5 min
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard sedation using meperidine and diazepam
Number of subjects: 175
Study: 15694808

Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Electrocoagulation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sharp dissection with ligation
Number of subjects: 36
Study: 12070543

Group type: EXPERIMENTAL
Intervention: Metformin (850mg twice daily) plus Clomiphene citrate (50mg, increasing to 200mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo plus Clomiphene citrate (50mg, increasing to 200mg)
Number of subjects: 28
Study: 10472229

Group type: EXPERIMENTAL
Intervention: Anaesthetic interventions classified by evidence level
Number of subjects: 0
Study: 7670451

Group type: EXPERIMENTAL
Intervention: Lactate supplementation (10 g of lactate as calcium, sodium, and potassium salts, twice a day for 3 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, twice a day for 3 weeks)
Number of subjects: 15
Study: 2073113

Group type: EXPERIMENTAL
Intervention: Aerosolized rimantadine at 20 micrograms/liter of air for 12 hours daily for 3 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Aerosolized rimantadine at 40 micrograms/liter of air
Number of subjects: 9

Group type: COMPARATOR
Intervention: Oral administration of rimantadine at 200 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Aerosolized rimantadine at 20 micrograms/liter of air
Number of subjects: 9
Study: 7015789

Group type: EXPERIMENTAL
Intervention: Racemic propranolol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 46
Study: 29618226

Group type: EXPERIMENTAL
Intervention: Rectus muscle reapproximation
Number of subjects: 280

Group type: COMPARATOR
Intervention: No rectus muscle reapproximation
Number of subjects: 280
Study: 28435222

Group type: EXPERIMENTAL
Intervention: 5 μg dexmedetomidine (BD group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.5 mL 0.9% normal saline (BN group)
Number of subjects: 50
Study: 26486256

Group type: EXPERIMENTAL
Intervention: Increases in diet self‐efficacy among AA women
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Increases in diet‐related social support and self‐efficacy, and family support to exercise among AA men
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Increases in friends' support to exercise and exercise‐related self‐efficacy among non‐AA women
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Increases in diet self‐efficacy among non‐AA men
Number of subjects: 588
Study: 23939663

Group type: EXPERIMENTAL
Intervention: Adapted simvastatin doses (ranging from 25 to 80 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard simvastatin dose (40 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low adapted simvastatin dose (12 mg) during CYP3A inhibition with ritonavir
Number of subjects: 18
Study: 20933491

Group type: EXPERIMENTAL
Intervention: DEC plus albendazole (DEC/ALB) combination
Number of subjects: 170

Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 170

Group type: COMPARATOR
Intervention: DEC
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 170
Study: 18613316

Group type: EXPERIMENTAL
Intervention: Quality assurance label on powdered infant milk formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provision of safe‐handling information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambiguity with incidence rate information
Number of subjects: 0
Study: 17704976

Group type: EXPERIMENTAL
Intervention: STW 5/Iberogast
Number of subjects: 0
Study: 15065831

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10567866

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo eyedrop
Number of subjects: 26
Study: 8690148

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic hypoglycemia (2.6 +/- 0.1 mmol/l, 47 +/- 1 mg/dl)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hyperinsulinemic euglycemia (4.8 +/- 0.1 mmol/l, 86 +/- 5 mg/dl)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stepped hypoglycemic clamps (4.7, 4.2, 3.6, 3.0, 2.8, 2.5, and 2.2 mmol/l)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stepped hypoglycemic clamps
Number of subjects: 16
Study: 1707413

Group type: EXPERIMENTAL
Intervention: Org 10172 (Lomoparan) 750 units subcutaneously every twelve hours until the ninth postoperative day
Number of subjects: 263

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 263